000889078 001__ 889078
000889078 005__ 20230111074308.0
000889078 0247_ $$2doi$$a10.3390/pharmaceutics12121247
000889078 0247_ $$2Handle$$a2128/27213
000889078 0247_ $$2altmetric$$aaltmetric:96648861
000889078 0247_ $$2pmid$$a33371500
000889078 0247_ $$2WOS$$aWOS:000602408600001
000889078 037__ $$aFZJ-2021-00014
000889078 082__ $$a610
000889078 1001_ $$0P:(DE-Juel1)175142$$aNeumaier, Felix$$b0$$eCorresponding author
000889078 245__ $$aNuclear Medicine in Times of COVID-19: How Radiopharmaceuticals Could Help to Fight the Current and Future Pandemics
000889078 260__ $$aBasel$$bMDPI$$c2020
000889078 3367_ $$2DRIVER$$aarticle
000889078 3367_ $$2DataCite$$aOutput Types/Journal article
000889078 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1613746884_13130
000889078 3367_ $$2BibTeX$$aARTICLE
000889078 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000889078 3367_ $$00$$2EndNote$$aJournal Article
000889078 520__ $$aThe emergence and global spread of COVID-19, an infectious disease caused by the novel coronavirus SARS-CoV-2, has resulted in a continuing pandemic threat to global health. Nuclear medicine techniques can be used for functional imaging of (patho)physiological processes at the cellular or molecular level and for treatment approaches based on targeted delivery of therapeutic radionuclides. Ongoing development of radiolabeling methods has significantly improved the accessibility of radiopharmaceuticals for in vivo molecular imaging or targeted radionuclide therapy, but their use for biosafety threats such as SARS-CoV-2 is restricted by the contagious nature of these agents. Here, we highlight several potential uses of nuclear medicine in the context of SARS-CoV-2 and COVID-19, many of which could also be performed in laboratories without dedicated containment measures. In addition, we provide a broad overview of experimental or repurposed SARS-CoV-2-targeting drugs and describe how radiolabeled analogs of these compounds could facilitate antiviral drug development and translation to the clinic, reduce the incidence of late-stage failures and possibly provide the basis for radionuclide-based treatment strategies. Based on the continuing threat by emerging coronaviruses and other pathogens, it is anticipated that these applications of nuclear medicine will become a more important part of future antiviral drug development and treatment.
000889078 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000889078 588__ $$aDataset connected to CrossRef
000889078 7001_ $$0P:(DE-Juel1)176188$$aZlatopolskiy, Boris D.$$b1
000889078 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b2
000889078 773__ $$0PERI:(DE-600)2527217-2$$a10.3390/pharmaceutics12121247$$gVol. 12, no. 12, p. 1247 -$$n12$$p1247$$tPharmaceutics$$v12$$x1999-4923$$y2020
000889078 8564_ $$uhttps://juser.fz-juelich.de/record/889078/files/Invoice_MDPI_pharmaceutics-1020747_1422.43EUR.pdf
000889078 8564_ $$uhttps://juser.fz-juelich.de/record/889078/files/pharmaceutics-12-01247-v3.pdf$$yOpenAccess
000889078 8767_ $$81020747$$92020-12-17$$d2021-01-20$$eAPC$$jZahlung erfolgt$$ppharmaceutics-1020747$$zBelegnr. 1200162154
000889078 909CO $$ooai:juser.fz-juelich.de:889078$$pdnbdelivery$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire
000889078 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)175142$$aForschungszentrum Jülich$$b0$$kFZJ
000889078 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b2$$kFZJ
000889078 9130_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000889078 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000889078 9141_ $$y2021
000889078 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000889078 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-29
000889078 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-29
000889078 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-08-29
000889078 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-08-29
000889078 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-08-29
000889078 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHARMACEUTICS : 2018$$d2020-08-29
000889078 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-08-29
000889078 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-08-29
000889078 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-29
000889078 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-08-29
000889078 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-29
000889078 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-08-29
000889078 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000889078 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-08-29
000889078 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-08-29
000889078 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-29
000889078 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-08-29
000889078 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-29
000889078 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
000889078 980__ $$ajournal
000889078 980__ $$aVDB
000889078 980__ $$aUNRESTRICTED
000889078 980__ $$aI:(DE-Juel1)INM-5-20090406
000889078 980__ $$aAPC
000889078 9801_ $$aAPC
000889078 9801_ $$aFullTexts